Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reissue Patent
2000-07-26
2003-07-01
Fredman, Jeffrey (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S005000, C435S091100, C435S091200, C536S023100, C536S024300, C536S024330, C536S024500, C514S04400A, C548S121000, 42
Reissue Patent
active
RE038169
ABSTRACT:
This invention pertains to sense-antisense nucleic acid complexes, particularly to sense-antisense nucleic acid complexes which are hyperstabilized with a selective binding agent.
Nucleic acids, which encode the genetic information of all cells and viruses, commonly occur in two forms, known as DNA and RNA. A chain of several bases of RNA or DNA is called an oligonucleotide or a polynucleotide, depending on its size. Two oligonucleotides or polynucleotides whose base sequences are complementary to one another can bind to one another into a double helix through a process called base-pairing.
So-called “antisense” oligonucleotides or probes have been investigated as a possible means for regulating gene expression. An antisense oligonucleotide is an oligonucleotide (usually a synthetic oligonucleotide introduced from an external source) whose sequence is complementary to that of a target sequence of DNA or RNA (usually RNA) of a cell or virus. Because the antisense probe is complementary to the target sequence, the two can bind into a double helix. This induced double helix inhibits the activity of the target sequence, at least temporarily. The inhibition can result from failure of the RNA-DNA heteroduplex to be recognized as a template for translation, or as a result of the activation of RNase H by the RNA-DNA duplex. RNase H hydrolyses RNA in an RNA/DNA duplex. RNase H occurs in some viruses including HIV, bacteria, and ubiquitously in plant and animal cells. Thus RNA bound in such an RNA/DNA heteroduplex can be inactivated either because it is not recognized as a single-stranded messenger RNA, or because it is hydrolyzed after the heteroduplex forms.
Antisense technology is expected to have important therapeutic applications directed toward a variety of diseases, possibly including cancer, viral and retroviral diseases, autoimmune diseases, and parasitic infections.
Some structurally modified antisense probes have also been tested for potential therapeutic activity. These modifications generally render them resistant to nucleases, enzymes which degrade nucleic acids. These modifications are most commonly made to the phosphodiester linkage connecting adjacent nucleotides, but some sugar analogs and “artificial” stereoisomers of sugar-base linkages have also been devised.
Unfortunately, the resulting increase in nuclease resistance has been offset by a reduction in the stability of the sense-antisense duplex. A more stable sense-antisense duplex would permit smaller doses of antisense oligonucleotides to be used with greater effect. Previous strategies to enhance the stability of sense-antisense duplexes have included the attachment of intercalating acridines or reactive agents such as alkylating agents or psoralens (which is photoactive), but these approaches have met with only limited success.
Prior antisense technologies relying on the exogenous application of antisense oligonucleotides have encountered problems with the stability of the antisense probe, with the uptake of the antisense probes by cells, and with the stability of the sense-antisense duplexes formed. The first of these limitations, stability of the probe, is believed to be due to the susceptibility of single-stranded nucleotides (with conventional phosphodiester or PO linkages) to digestion by nucleases present in serum and in cell culture medium. The second limitation, uptake of the probes by cells, is believed to be due to poor uptake of the polyanionic (i.e., electronically charged) oligonucleotide through the cell membrane, although some studies have suggested the existence of an “oligonucleotide pump” which may transport charged oligonucleotides. Modified internucleotide linkages, such as those using methyl phosphonate (MP) or phosphorothioate (PS) linkages, have partially overcome the first two limitations. These modifications can result in improved resistance to nucleases, and somewhat enhanced cell penetration. See Uhlmann et al., “Antisense Oligonucleotides: A New Therapeutic Principle,” Chemical Reviews, vol. 90, no. 4, pp. 543-584 (1990); and Cohen, “Oligonucleotides as Therapeutic Agents,” Pharmac. Ther., vol. 52,pp. 211-225 (1991), the entire disclosures of both of which are incorporated by reference.
But treating the first two limitations has increased the difficulties caused by the third limitation, the problem of poor stability of sense-antisense hybrids (as measured by T
m
, the strand separation temperature). With methylphosphonate antisense structures, an additional problem was also found: the antisense-sense duplexes did not stimulate RNase H.
Uhlmann et al., “Antisense Oligonucleotides: A New Therapeutic Principle,” Chemical Reviews, vol. 90, no. 4, pp. 543-584 (1990) review generally the field of antisense technology, including the use of modified backbones in the oligonucleotides; the tethering of intercalating agents and psoralen; effects on RNase H activation; and limitations and strengths of the prior antisense technology.
Hélène, “Artificial Control of Gene Expression by Oligodeoxynucleotides Covalently Linked to Intercalating Agents,” Br. J. Cancer, vol. 60, pp. 157-160 (1989); and Lee et al., “Interaction of Psoralen-Derivatized Oligodeoxyribonucleoside Methylphosphonates with Single-Stranded DNA,” Biochemistry, vol. 27, no. 9, pp. 3197-3203 (1988) discuss the use of crosslinking agents (such as psoralens and alkylators) and acridines linked to antisense oligonucleotides, with limited increases observed in the resulting stabilization of the duplexes.
Cohen, “Oligonucleotides as Therapeutic Agents,” Pharmac. Ther., vol. 52, pp. 211-225 (1991) discusses uses of oligonucleotides as therapeutic agents, including uses in triple-strand binding. Cohen noted that precious approaches to antisense technology have been more successful in preventing translation than in preventing elongation.
Reynolds et al., “The Chemistry, Mechanism of Action and Biological Properties of CC-1065, A Potent Antitumor Antibiotic,” J. Antibiotics, vol. 39, No. 3, pp. 319-334 (1986) reviews the properties of CC-1065 and routes for its synthesis.
REFERENCES:
patent: 4169888 (1979-10-01), Hanka et al.
patent: 4921788 (1990-05-01), Deutsch
patent: 5340716 (1994-08-01), Ullman et al.
Boger, D. et al., “CC-1065 Partial Structures,”J. Org. Chem., vol. 57, pp. 1277-1284 (1992).
Boger et al., “Synthesis and Evaluation of Aborted and Extended CC-1065 Functional Analogues,” J. Am. Chem. Soc., vol. 112, pp. 4623-4632 (1990).
Cohen, “Oligonucleotides as Therapeutic Agents,” Pharmac. Ther., vol. 52, pp. 211-225 (1991).
Gura “Antisense has Growing Pains,” pp. 575-577 (1995).
Hélène, “Artificial Control of Gene Expression by Oligodeoxynucleotides Covalently Linked to Intercalating Agents,” Br. J. Cancer, vol. 60, pp. 157-160 (1989).
James, “Antiviral Chemistry and Chemotherapy,” 2, pp. 191-214 (1991).
Kim et al., Dissertation Abstracts Int. 55 (3B), p. 829 (1993).
Krueger et al., “The Binding of CC-1065 to Poly- and Oligonucleotides,” Biopolymers, vol. 24, pp. 1549-1572 (1985).
Lee et al., “Interaction of Psoralen-Derivatized Oligodeoxyrlbonucleoside Methylphosphonates with Single-Stranded DNA,” Biochemistry, vol. 27, No. 9, pp. 3197-3203 (1988).
Lee et al., “Molecular Recognition between Oligopeptides and Nucleic Acids,” J. Am. Chem. Soc., vol. 110, pp. 3641-3649 (1988).
Lewin, B., Genes IV, Chapter 5, “The Topology of Nucleic Acids,” Oxford University Press, pp. 82-84 (1990).
Miller et al., “Anticancer Drug Design,” 2, pp. 117-128 (1987).
Reynolds et al., “The Chemistry, Mechanism of Action and Biological Properties of CC-1065, A Potent Antitumor Antibiotic,” J. Antibiotics, vol. 39, No. 3, pp. 319-334 (1986).
Roberts et al., “Stability and Properties of Double and Triple Helices: Dramatic Effects of RNA or DNA Backbone Composition,” Science, vol. 258, pp. 1463-1466 (1992).
Swenson et al., “Mechanism of Interaction of CC-1065 (NSC 298223) with DNA,” Cancer Research, vol. 42, pp. 2821-2828 (1982).
Uhlmann et al., “Antisense Oligonucleotides: A New Therapeutic Principle,” Chemical Reviews, vol. 90, No. 4, pp. 543-584 (1990).
W
Board of Supervisors of Louisana State University and Agricultur
Fredman Jeffrey
Runnels John H.
LandOfFree
Hyperstabilizing antisense nucleic acid binding agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hyperstabilizing antisense nucleic acid binding agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hyperstabilizing antisense nucleic acid binding agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3059022